This Promising GLP-1 Drug Could Renew Novo Nordisk Hope
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...
GLP-1 Drugs
GLP-1 Drugs tag page compiles 4 articles on how obesity drugs impact costs, shares, and budgeting. Find practical insights to safeguard your finances as pharmaceutical trends shape prices and plans.
6 articlesHims Hers Really Growth Stock Faces Reality Check Now
Hims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
Hims Hers Health Shares Rally on Novo Nordisk Deal
Hims Hers Health shares jumped after news of a Novo Nordisk collaboration. This guide breaks down what the deal could...
GLP-1s Cure Hunger More, Study Finds Broad Impact
A sweeping real-world study of roughly 600,000 GLP-1 users finds cravings for cigarettes, alcohol, and other addictio...
Hims Hers Snaps Losing Streak as EPS Beat Fails Again
Hims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...